Dachaigh › Lymphoma Cealla B Mòr Sgaoilte › North Carolina
Sgrùdaidhean clionaigeach Lymphoma Cealla B Mòr Sgaoilte ann an North Carolina
Tha 20 sgrùdaidhean airson Lymphoma Cealla B Mòr Sgaoilte a’ lorg phàirtichean aig làraichean ann an North Carolina.
Bailtean ann an North Carolina
Teacsa sgrùdaidh oifigeil (Beurla)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Novant Health Cancer Institute- Hematology, Charlotte
- Duke Blood Cancer Center, Durham
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06500273A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- East Carolina University ( Site 0159), Greenville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Duke University Medical Center, Durham
- East Carolina University, Greenville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of North Carolina Medical Center ( Site 0136), Chapel Hill
- Novant Health Presbyterian Medical Center ( Site 0177), Charlotte
- Novant Health Forsyth Medical Center ( Site 0206), Winston-Salem
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06890884A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Lùna 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
A’ fastadhÌre 1/2
Aoisean 13 gu 90 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Lùna 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT04792489Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Wake Forest University Health Sciences, Winston-Salem
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Iuch 2026 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Iuch 2026 · NCT05131022Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- agus 4 a bharrachd
A’ fastadhSgrùdadh amharc
Aoisean 65 agus nas sine · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT01137825Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gearr 2026 · NCT04775745Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- Wake Forest University Health Sciences, Winston-Salem
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Gearr 2026 · NCT05633615Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 27 Dàmh 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2025 · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2025 · NCT05107674Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Sult 2024 · NCT06238648DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Brody School of Medicine at East Carolina University, Greenville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Gibl 2023 · NCT04920617Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.